COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin

19Citations
Citations of this article
102Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A 40-year-old man presented with altered mental status after a recenthospitalisation for COVID-19 pneumonia. Cerebrospinal fluid (CSF) analysis showed lymphocytosis concerning for viral infection. The CSF PCR for SARS-CoV-2 was negative, yet this could not exclude COVID-19 meningoencephalitis. During hospitalisation, the patient's mentation deteriorated further requiring admission to the intensive care unit (ICU). Brain imaging and electroencephalogram (EEG) were unremarkable. He was, thus, treated with intravenous immunoglobulin (IVIg) for 5 days with clinical improvement back to baseline. This case illustrates the importance of considering COVID-19's impact on the central nervous system (CNS). Haematogenous, retrograde axonal transport, and the effects of cytokine storm are the main implicated mechanisms of CNS entry of SARS-CoV-2. While guidelines remain unclear, IVIg may be of potential benefit in the treatment of COVID-19-associated meningoencephalitis.

Author supplied keywords

Cite

CITATION STYLE

APA

El-Zein, R. S., Cardinali, S., Murphy, C., & Keeling, T. (2020). COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin. BMJ Case Reports, 13(9). https://doi.org/10.1136/bcr-2020-237364

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free